Veracyte completes acquisition of HalioDX

Aug. 5, 2021

Veracyte, which specializes in genomic cancer testing, announced that the company has completed its acquisition of HalioDx, an immuno-oncology diagnostic company.

HalioDx, which has products in colon and lung cancer, has become a wholly owned subsidiary of Veracyte.

In February, Veracyte announced plans to acquire Decipher Biosciences, a commercial-stage precision oncology company focused on urologic cancers.

Visit Veracyte for more news